(Alliance News) - PureTech Health PLC on Tuesday said its Akili Interactive Labs Inc affiliate has published positive results from a pivotal study of AKL-T01 in children with attention deficit hyperactivity disorder, or ADHD.
AKL-T01 is a digital therapeutic which uses an action video game "designed to target and activate the fronto-parietal network in the brain, known to play a key role in cognitive function and attention". Akili filed for US clearance for AKL-T01 as a treatment for children with ADHD in 2018 but this has not yet been granted.
The pivotal study, named Stars-ADHD, involved 348 children between 8 and 12 years old with an ADHD diagnosis in the largest clinical trial of the treatment so far. Half of the children were given AKL-T01 and the other half an "active control".
Results of the study, which were published in the Lancet Digital Health journal, showed AKL-T01 improved attention and functional impairment by objective measures, with parents also observing an improvement.
PureTech Chief Innovation Officer Eric Elenko said: "These complete results provide compelling insights and further validation for AKL-T01 for the treatment of inattention in children with ADHD. It also builds on the recently reported findings from Akili's Stars-ADHD Adjunctive study, which demonstrated additional promise for AKL-T01 as both a monotherapy and in combination with stimulant medications. It is exciting to see the mounting data for AKL-T01 which validates its potential."
Shares in PureTech were down 1.8% at 330.00 pence in London on Tuesday.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)